60521-91-7

Basic information

• Product Name: Ac-Phe(4-NHAc)-OMe
• Synonyms: Ac-Phe(4-NHAc)-OMe
• CAS NO: 60521-91-7
• Molecular Weight: 278.308
• Mol File: 60521-91-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Ac-Phe(4-NHAc)-OMe(CAS DataBase Reference)
• NIST Chemistry Reference: Ac-Phe(4-NHAc)-OMe(60521-91-7)
• EPA Substance Registry System: Ac-Phe(4-NHAc)-OMe(60521-91-7)

Safety Data

• Hazardous Substances Data: 60521-91-7(Hazardous Substances Data)

Upstream product

• 36097-39-9 (S)-methyl 2-acetamido-3-(4-nitrophenyl)propanoate 
• 108-24-7 acetic anhydride 
• 36097-42-4 2(S)-acetylamino-3-(4-amino-phenyl)-propionic acid methyl ester 
• 105052-56-0 methyl (S)-2-amino-3-(4-aminophenyl)propanoate 
• 17363-92-7 N-acetyl-4-nitro-L-phenylalanine 

Downstream Products

• 864238-42-6 D,L-4-Acetamido-N-acetyl-3-nitrophenylalanine methyl ester 
• 864238-27-7 Fmoc-Phe(4-NH₂-3-NO₂)-OH 
• 942218-75-9 C₁₄H₁₇ClN₂O₄ 

Relevant articles and documents

COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid

Novel pharmaceutical compositions are disclosed. The compositions comprise an aryl substituted alanine and a substituted phenyl hydrazino propionic acid. The compositions are useful for treating hypertension.